Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Acquisition strengthens merck’s oncology pipeline with VLS-101, an investigational antibody-drug conjugate to treat hematological malignancies and solid tumors.
Lead Product(s): VLS-101
Therapeutic Area: Oncology Product Name: VLS-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $2,750.0 million Upfront Cash: $2,750.0 million
Deal Type: Acquisition November 05, 2020
Details:
The Phase 2 trial will enroll patients with previously treated solid tumors. Patients will receive VLS-101 2.5 mg/kg intravenously once every three weeks for as long as they are safely benefiting from VLS-101 therapy.
Lead Product(s): VLS-101
Therapeutic Area: Oncology Product Name: VLS-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Food and Drug Administration (FDA) has granted the company Fast Track and Orphan Drug designation for VLS-101 for the treatment of patients with mantle cell lymphoma (MCL).
Lead Product(s): VLS-101
Therapeutic Area: Oncology Product Name: VLS-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Oversubscribed funding round to advance the development of investigational, first-in-class antibody-drug conjugates and bispecific antibodies targeting ROR1, a novel oncology target, across multiple cancer types.
Lead Product(s): VLS-101
Therapeutic Area: Oncology Product Name: VLS-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Matrix Capital Management
Deal Size: $137.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 08, 2020